Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Phase II Study for Bone Marrow Protection, Safety, and Efficacy of Trilaciclib Combined With Eribulin in Locally Advanced or Metastatic Triple-negative Breast Cancer After at Least Two Prior Chemotherapy Regimens

NCT07255612 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT07255612
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07255612 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Phase II Study for Bone Marrow Protection, Safety, and Efficacy of Trilaciclib Combined With Eribulin in Locally Advanced or Metastatic Triple-negative Breast Cancer After at Least Two Prior Chemotherapy Regimens
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 4, 2026
Completion date
December 1, 2026
Enrollment
29 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer